Most Read Articles
Kavitha G. Shekar, 04 May 2016
Cannabis use during pregnancy increases the risk of maternal anaemia, and causes several adverse outcomes in infants like low birth weight (LBW), and increased neonatal intensive care unit (NICU) admissions, show findings of a systematic review and meta-analysis.
26 Feb 2017
Placement of cervical pessary in women with short cervices and singleton pregnancies does not lower the risk of having preterm births, according to the results of a meta-analysis.
01 Jan 2015
Iron supplementation has long established its role from among women of child-bearing age. This study, however, looked into the effect of zinc when in combination with iron.
Roshini Claire Anthony, 07 Sep 2016

Estrogen receptor α (ESR1) mutations Y537S and D538G are associated with reduced overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, according to findings of a secondary analysis of the BOLERO-2* clinical trial.

Elagolix safe, effective for heavy menstrual bleeding

16 Oct 2017

Elagolix is safe and effective for reducing heavy menstrual bleeding in females with fibroids, a new dose-ranging, multiple-cohort study has shown.

Investigators randomized 271 females (mean age 41.8 years) to receive elagolix alone (n=160), elagolix and an add-back therapy (n=61) or placebo (n=50). The primary study outcome was the mean and percentage change in menstrual blood loss (MBL).

Females who received elagolix had significantly larger reductions in MBL from baseline to last complete treatment cycle compared with those who received placebo (p<0.01). Inclusions of add-back on therapies also reduced the MBL compared with placebo, but in magnitudes lower than those in patients who took elagolix only.

Elagolix also exerted a dose-dependent suppressive effect on heavy menstrual bleeding, with those receiving the 300 mg twice-daily doses experiencing the most suppression. Indeed, even if the total daily dose was the same, twice-daily dosing resulted in similar or greater MBL reductions.

Majority (84.4 to 96.8 percent) of females in the elagolix group had menstruation within 90 days of the last dose, resulting in a median range of time to return to menstruation of 25 to 30 days. In the placebo group, 93.3 to 100 percent of the females returned to menstruation within 90 days, and the median range of time was 11 to 19 days.

“These results provide a rationale for phase IIb and III clinical trials of longer duration to further evaluate the safety and efficacy of elagolix with add-back regimens,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Kavitha G. Shekar, 04 May 2016
Cannabis use during pregnancy increases the risk of maternal anaemia, and causes several adverse outcomes in infants like low birth weight (LBW), and increased neonatal intensive care unit (NICU) admissions, show findings of a systematic review and meta-analysis.
26 Feb 2017
Placement of cervical pessary in women with short cervices and singleton pregnancies does not lower the risk of having preterm births, according to the results of a meta-analysis.
01 Jan 2015
Iron supplementation has long established its role from among women of child-bearing age. This study, however, looked into the effect of zinc when in combination with iron.
Roshini Claire Anthony, 07 Sep 2016

Estrogen receptor α (ESR1) mutations Y537S and D538G are associated with reduced overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, according to findings of a secondary analysis of the BOLERO-2* clinical trial.